Remove Bioinformatics Remove Clinical Research Remove Doctors Remove FDA Approval
article thumbnail

STAT+: Foundation charges cancer patients $83,000 for unproven but promising experimental drug

STAT News

Determined to prove his doctors wrong, Aldrich got his tumor genetically sequenced and arranged for a German biotech, CeGaT, to design an experimental neoantigen vaccine that he received in 2019, according to Jacobs and an account Aldrich gave to an online cancer publication. “It really was a choice of this or nothing.”

article thumbnail

Who are the AACR Scientific Achievement Award winners?

Drug Discovery World

He is being recognised for illuminating research contributions to defining the links between chromosomal abnormalities and cancer, including his discovery of TMPRSS2-ETS gene fusions in prostate cancer, and for pioneering the use of pathological and bioinformatic methodologies to diagnose and track prostate cancer onset and progression.